A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Pilot Study of the Safety and Efficacy of RDC-0313 in Adults With Binge Eating Disorder.

Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Pilot Study of the Safety and Efficacy of RDC-0313 in Adults With Binge Eating Disorder.

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Oct 2014

At a glance

  • Drugs Samidorphan (Primary)
  • Indications Binge-Eating Disorder
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Alkermes
  • Most Recent Events

    • 08 Jul 2011 Based on the results from this trial, Alkermes discontinued the development of ALKS 33 for the treatment of binge eating disorders.
    • 16 Jun 2011 Actual end date (Jun 2011) added as reported by ClinicalTrials.gov.
    • 16 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top